Because the dysregulation of cellular sumoylation processes are a feature of a variety of diseases7–15, including EBV-associated lymphomas, understanding how LMP1 targets the different steps of the process may help identify potential new therapeutic targets to treat LMP1-expressing EBV-associated lymphomas. This evidence concerns the gene PDLIM7 and lymphoma.